This study is currently not recruiting participants.

A Phase I Study of Imetelstat a Telomerase Inhibitor in Children with Refractory or Recurrent Solid Tumors and Lymphoma

Investigating the Impact of an Investigational Medication on Resistant Tumors

Not Recruiting
1 years - 21 years
All
Phase N/A

Brief description of study.

We are testing new experimental drugs such as imetelstat in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy.

Detailed description of study

We are testing new experimental drugs such as imetelstat in the hopes of finding a drug that may be effective against tumors that have come back or that have not responded to standard therapy.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lymphoma
  • Age: 1 years - 21 years
  • Gender: All

This study investigates the effectiveness of an investigational medication on tumors that have returned or not responded to standard treatments. Tumors are abnormal growths of tissue that can be cancerous. The study aims to find out if the investigational medication can be a potential treatment option for these types of tumors.

Participants in the study will receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study will compare the results of those receiving the investigational medication with those receiving the placebo to determine its effectiveness.

  • Who can participate: Eligibility criteria are not specified in the provided description.
  • Study details: Participants will be randomly assigned to receive either the investigational medication or a placebo. A placebo is an inactive substance that looks like the investigational medicine but does not contain any medicine. The study will compare the results of those receiving the investigational medication with those receiving the placebo to determine its impact.
Updated on 19 Feb 2024. Study ID: 1106005712

Interested in the study?

Select a study center that’s convenient for you, and get in touch with the study team.

Connect with the study team